The LRIF1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line, designed for disruption of the LRIF1 gene. This genetically engineered polyclonal pool is generated through CRISPR/Cas9-mediated gene disruption, providing a versatile loss-of-function model for investigating LRIF1-dependent cellular processes. The polyclonal nature ensures representation of a heterogeneous population of knockout alleles, making it suitable for population-level analyses without requiring monoclonal selection. This product enables researchers to dissect the functional roles of LRIF1 in a well-characterized B-cell lymphoma background.
Raji cells are a widely employed human B lymphoblastoid cell line originally established from a Burkitt lymphoma patient. These EBV-positive cells maintain characteristics of mature B lymphocytes and are extensively utilized in immunological, oncological, and virological research. Their robust growth and well-documented genomic landscape make them an ideal host for knockout studies, particularly for investigating B-cell signaling, lymphomagenesis, and host-pathogen interactions.
LRIF1 (Ligand-Dependent Nuclear Receptor-Interacting Factor 1) serves as a critical nuclear receptor cofactor, mediating ligand-dependent transcriptional regulation. The protein interacts directly with heterochromatin protein 1 (HP1) family members??CBX1, CBX3, and CBX5??and the structural maintenance of chromosomes protein SMCHD1, thereby organizing chromatin structure and facilitating heterochromatin establishment. Through these interactions, LRIF1 modulates the expression of nuclear receptor target genes and heterochromatin-associated genes, integrating signals from nuclear receptor ligands to chromatin organization. Upstream regulators include nuclear receptor ligands such as retinoids and thyroid hormones, while downstream effects involve transcriptional regulation of specific target genes. LRIF1 thus links nuclear receptor signaling pathways with epigenetic chromatin remodeling machinery, influencing gene expression programs in a ligand- and context-dependent manner.
In the Raji B-lymphoma context, LRIF1 disruption enables exploration of the crosstalk between nuclear receptor pathways and chromatin dynamics in B-cell biology. Given the established role of heterochromatin organization in gene silencing and genomic stability, LRIF1 knockout may reveal alterations in the epigenetic landscape that contribute to lymphomagenesis or B-cell differentiation. Raji cells provide a relevant model for B-cell malignancies, and LRIF1??s interaction with SMCHD1, a protein implicated in facioscapulohumeral muscular dystrophy, further extends the model??s utility to studies of nuclear architecture and disease-associated epigenetic mechanisms in a lymphoid environment.
This polyclonal knockout cell population supports a broad range of experimental approaches, including Western blotting to assess LRIF1 and HP1 protein levels, RT-qPCR for measuring nuclear receptor target gene expression, chromatin immunoprecipitation (ChIP-qPCR) for mapping chromatin occupancy, immunofluorescence for nuclear localization studies, and co-immunoprecipitation to validate LRIF1-HP1 interactions. Additionally, RNA-sequencing (RNA-seq) transcriptome analysis enables comprehensive profiling of LRIF1-dependent gene networks. These tools facilitate studies in nuclear receptor signaling, chromatin remodeling, epigenetic regulation, and B-cell lymphoma biology, as well as screening for modulators of heterochromatin assembly. For further technical details or to discuss custom modifications, please contact Ascent Research.
